{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 29,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a combination of an additive equation for the value prop and a chevron-based timeline for lifecycle management.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/17",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.95,
        "x": 0.025,
        "y": 0.185
      },
      "kind": "diagram",
      "text": "AMPHOTERICIN B + ORAL ADMINISTRATION + LACK OF NEPHROTOXICITY = Safe, long-term oral step-down Tx with a potent fungicidal agent",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e347c5a-26ff-414a-b317-c29b95585fb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.025,
        "y": 0.34
      },
      "kind": "diagram",
      "text": "LIFE CYCLE MANAGEMENT: Phase 2 (Cryptococcal Meningitis), Phase 3 (Invasive Aspergillosis), LCM (Treatment of Other IFIs, Prophylaxis)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebebe862-6d98-4de7-b7a9-8a81e443cd7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.025,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Near-Term Development Strategy: Focused strategy on Phase 3 registration trial in Invasive Aspergillosis in patients with limited or no treatment options under the Limited Population Pathway for Antifungal Drugs (LPAD)*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54d6c5d0-d3a8-4954-bf36-073b735c8099",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.228,
        "x": 0.747,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* Evaluated at time of NDA filing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2301d1f0-556a-4913-ac1e-cc67775efb98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.334,
        "x": 0.036,
        "y": 0.065
      },
      "kind": "title",
      "text": "MAT2203 Value Proposition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e2c5bae-43a9-482a-915a-02554703542a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Value Proposition Canvas",
      "slug": "value-proposition-canvas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f09685c2-b984-4b40-9f6b-595018d2c6de",
      "evidence": "The slide outlines the value proposition of MAT2203, including its development strategy and potential benefits.",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "3673bfe9-0dbb-4518-a27f-b74ec75a6146",
      "evidence": "Chevron-based progression of clinical phases",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c020a8cd-19c2-4f66-b8fd-1a6de00826c3",
      "evidence": "The regulatory and development strategy for MAT2203 and the LNC platform are presented",
      "position": 2,
      "objective": "What are the near-term milestones and potential for growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}